Fundamentals of Hematopoietic Stem Cell Transplantation 2014
Grapevine, TX US
February 26, 2014 to February 27, 2014
Hematopoietic cell transplantation (HCT) is the only known curative therapy for many patients with hematologic malignancies and other blood, immune system, and metabolic disorders. In the United States each year, more than 20,000 HCTs are performed. As a result of advances in supportive care and transplantation techniques, this number is expected to increase significantly. HCT patients are on highly complex medication regimens and many of them are receiving long‐term follow up in the community. Practitioners working with HCT patients must be skilled in the management of transplant medication drug‐drug and drug‐food interactions, therapeutic drug monitoring, recognition and management of adverse effects, provision of supportive care, and selection of appropriate medications.
ACCME Accreditation Statement:
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the Medical College of Wisconsin and the National Marrow Donor Program. The Medical College of Wisconsin is accredited by the ACCME to provide continuing medical education for physicians.
AMA Credit Designation Statement:
The Medical College of Wisconsin designates this Live Activity for a maximum of 16.25 AMA PRA Category 1 Credit(s) ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Hours of Participation for Allied Health Care Professionals
The Medical College of Wisconsin designates this activity for up to 16.25 hours of participation for continuing education for allied health professionals.
This meeting was supported by an Unrestricted Education Grant from Amgen.
Target Audience
- Physicians
- Fellows
- Residents
- Nurses
- Pharmacists
- NP/PAs
Learning Objectives
- Describe the advantages and disadvantages of the available strategies for stem cell mobilization
- Outline commonly used preparative regimens, describing the expected toxicity profiles of the different approaches
- Review the current challenges in the management of nausea and vomiting in the HCT population, and outline antiemetic strategies to minimize nausea and vomiting
- Appraise the appropriateness of patient eligibility for HCT based on disease‐specific transplantation outcomes
- Describe strategies available for disease control post HCT
- Describe the management of common toxicities of HCT, including mucositis, nutritional statusrelated complications, and sinusoidal obstructive syndrome
- Discuss the common bacterial pathogens, prophylaxis strategies, and treatment approaches in patients undergoing HCT
- Review the incidence of invasive fungal infections in HCT patients, and describe treatment strategies (prophylaxis, empiric treatment, and treatment of documented fungal infections) in HCT patients
- Discuss the incidence, prophylaxis, and treatment of common viral infections in HCT patients
- Describe risk factors for, prevention strategies, treatment strategies, and common manifestations of acute graft‐versus‐host disease (GVHD)
- Describe risk factors for, prevention strategies, treatment strategies, and common long term complications of chronic GVHD
- Describe the common pulmonary complications associated with HCT, and identify common approaches to treatment of these complications
- Review the long‐term complications associated with patient undergoing HCT
Gaylord Texan Resort & Convention Center
1501 Gaylord Trail
Grapevine, TX
76501
United States
Gaylord Texan Resort and Convention Center
1501 Gaylord Trail, Grapevine, TX 76051
(817) 778-1000
Planning Committee:
J. Douglas Rizzo, MD, MS
Elizabeth Murphy, EdD, RN
Lyndsey Aspaas, BS, CHTC
Michael Westmoreland, PharmD, BCOP
Terri Davidson, PharmD
Julie Marino
Helen Leather, BPharm
Tracey Walsh-Chocolaad, PharmD
Speakers:
Zahra Mahmoudjafari, PharmD, BCOP
Kristin Held, PharmD, BCOP
Susie Liewer, PharmD, BCOP
Sarah Perreault, PharmD, BCPS, BCOP
Ryan Bookout, PharmD, BCPS, BCOP
Alex Ganetsky, PharmD, BCOP
Kamakshi Rao, PharmD, BCOP, CPP
Valkal Bhatt, PharmD, BCOP
Michael Westmoreland, PharmD, BCOP
Susannah Koontz, PharmD, BCOP
Patrick Kiel, PharmD, BCPS, BCOP
James Hart, PharmD, BCOP
Amber Bradley, PharmD, BCOP
Amber Lawson, PharmD, BCOP
Angela Hsieh, PharmD, BCOP
Kelly Gregory, PharmD, BCOP
Rebecca Tombleson, PharmD
All persons in control of content have NO relevant financial relationships to disclose with the exception of the following person(s):
Available Credit
- 16.25 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 16.25 Hours of ParticipationHours of Participation credit.
Accreditation Period
Course opens:
01/01/2014
Course expires:
05/30/2014